Scholarlink

<p>Gastric cancer remains a major global health burden due to its high proliferation, metastasis, and chemoresistance, which severely limit the therapeutic efficacy of conventional treatments. Albumin-bound paclitaxel (Abraxane) offers improved solubility and reduced systemic toxicity compared to free paclitaxel, yet its in vivo delivery efficiency remains suboptimal. In this study, a novel nanoparticle platform (HA-ATPMS-1@CP1@PTX) based on a Co(II)-coordination polymer (CP1) functionalized with hyaluronic acid and ATPMS-derived compound 1 was developed to enhance paclitaxel delivery. The system exhibited favorable pH-responsive release, excellent optical/electrochemical activity, and high biocompatibility. CCK-8 assays on three gastric cancer cell lines (MGC-803, SGC-7901, BGC-823) demonstrated that the NP-Pac group achieved superior inhibition of cell proliferation compared to both free drug and blank controls. These findings underscore the potential of HA-ATPMS-1@CP1@PTX as an advanced, multifunctional nanocarrier for improving therapeutic outcomes in gastric cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Study on organosilicon composite carrier loaded with paclitaxel for inhibition of gastric cancer cell proliferation

  • 期刊论文

  • 发表日期：

    2026年6月1日

查看全文
  • Xucheng Liu,
  • Liuqun Shan,
  • Gongming Cheng,
  • Wenjie Shi,
  • Jianbo Han

摘要

Gastric cancer remains a major global health burden due to its high proliferation, metastasis, and chemoresistance, which severely limit the therapeutic efficacy of conventional treatments. Albumin-bound paclitaxel (Abraxane) offers improved solubility and reduced systemic toxicity compared to free paclitaxel, yet its in vivo delivery efficiency remains suboptimal. In this study, a novel nanoparticle platform (HA-ATPMS-1@CP1@PTX) based on a Co(II)-coordination polymer (CP1) functionalized with hyaluronic acid and ATPMS-derived compound 1 was developed to enhance paclitaxel delivery. The system exhibited favorable pH-responsive release, excellent optical/electrochemical activity, and high biocompatibility. CCK-8 assays on three gastric cancer cell lines (MGC-803, SGC-7901, BGC-823) demonstrated that the NP-Pac group achieved superior inhibition of cell proliferation compared to both free drug and blank controls. These findings underscore the potential of HA-ATPMS-1@CP1@PTX as an advanced, multifunctional nanocarrier for improving therapeutic outcomes in gastric cancer treatment.